Specs Compound Handling BV (Specs) announced that eMolecules made a bid to acquire 100% of the company’s shares. The shareholders of Specs – a trader in medical compounds for research – decided to accept this offer of €11 per share in cash. The last known number of issued shares is 1.7 million, bringing the take-over sum to €18.7 million. This take-over also includes the purchase of the depository receipts (DRs) of Specs shares on the NPEX exchange. The bid implies a premium of 18% on the last share price of €9.30 or 10% on Specs’s listing price of €10.
As part of the acquisition, the undisclosed buyer acquires all shares of Specs, and Specs withdraws the associated DRs. The last trading day for Specs Compound Handling was on Tuesday, May 23, 2023. “The activities of both companies are complementary. The acquisition aligns well with Specs’ growth plans presented during the NPEX listing”, according to Johan Tijhuis, CEO of Specs.
NPEX is a portfolio company of Icecat Capital since last month, which helps SME business to raise growth capital from retail and professional investors.
Disclaimer: This news post is for informational purposes only. It should not be considered as financial advice or a recommendation to buy or sell securities. Readers are encouraged to conduct their own research and consult with a financial advisor before making any investment decisions.
Meta is giving frequent Facebook Marketplace sellers a dedicated place to run their selling activity.…
Sprint 101 was a consolidation sprint. Where Sprint 100 opened several fronts, this release brings…
Artificial intelligence is becoming an increasingly common shopping companion. Consumers now rely on AI assistants…
Spreadsheets are often the most practical place to start managing product data. Excel and Google…
The European Union has reached an important milestone in its product transparency agenda. The Digital…
Just over a week after OpenAI disclosed that one of its autonomous AI agents escaped…